vTv Therapeutics Inc (NASDAQ: VTVT) is having an incredibly strong start to the trading session this morning, and for good reason. The company announced the coming presentation of clinical data, exciting investors and sending the stock screaming for the top. Today, we’ll talk about:
- The coming presentations;
- what we’re seeing from VTVT stock as a result; and
- what we’ll be watching for ahead.
VTVT Runs For The Top On Coming Presentation
As mentioned above, vTv Therapeutics is having an incredibly strong start to the trading session this morning after the comapny announced that it will be providing a presentation soon. In a press release issued early this morning, the company said that it will deliver an oral presentation and present a poster at the 11th Clinical Trials on Alzheimer’s Disease (CTAD) conference between October 24 and October 27.
In the release, VTVT said that the oral presentation will detail the results from the Phase 3 STEADFAST study of azeliragon in patients with mild Alzheimer’s disease. The company also said that a subgroup analysis of its STEADFAST trial will be presented in a poster. Of course, the new data coming from VTVT is exciting investors who are pushing the stock upward.
What We’re Seeing From The Stock
One of the first lessons that we learn when we start to dig into the market is that the news leads to moves. In the case of vTv Therapeutics, the news proved to be positive. After all, the data must be positive if it has been accepted for both an oral and poster presentation at a medical conference. So, it comes as no surprise to see that excited investors are pushing the stock on a run for the top. As is normally the case, our partners at Trade Ideas were the first to alert us to the gains. Currently (8:32), VTVT is trading at $4.12 per share after a gain of $1.27 per share or 44.56% thus far today.
Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!
What We’ll Be Watching For Ahead
Moving forward, the CNA Finance team will continue to keep a close eye on VTVT. In particular, we’re interested in following the data surrounding the STEADFAST clinical trial and the continued development of azeliragon as the treatment seems to be yielding promising results. Nonetheless, we’ll continue to follow the story closely and bring the news to you as it breaks!
Never Miss The News Again
Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!